AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 07/13/20

DBV Technologies Reports Positive Extension Study Results DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Pea...

Lannett ( LCI -9.1% ) said it will cut 80 positions, ~8.5% of its total workforce, over concerns that it may face pricing pressure in fiscal 2021 on certain key products, including generic Fluphenazine product. More news on: Lannett Company, Inc., Amneal Pharmaceuticals, Inc....

FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Brann...

Amneal Pharmaceuticals (NYSE: AMRX ) announces the FDA nod for its generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time...

Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...

A coalition of 51 attorneys general in the U.S. has filed an antitrust complaint  in federal court against 26 companies making generic dermatology drugs and 10 executives at these firms claiming wide-spread price-fixing, marketing allocating and bid-rigging related to over 80 different...

A just-published study in the journal Lancet may dampen the enthusiasm for using chloroquine and hydroxychloroquine to treat COVID-19 patients. More news on: Mylan N.V., Sanofi, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...

With earnings season in the rear-view mirror for the specialty pharmaceutical sector, J.P. Morgan is updating its positioning on the sector as the COVID-19 pandemic marches on - reiterating its favorites in the area and issuing downgrades to a couple of companies facing challenges. More ne...